There are no clinical data to support that existing tumor biomarkers, including carbohydrate antigen 125 (CA125), CA19-9, and carcinoembryonic antigen (CEA), are effective for the diagnosis of early gastric cancer 2. This evidence concerns the gene CEACAM5 and neoplasm.